国际呼吸杂志
國際呼吸雜誌
국제호흡잡지
INTERNATIONAL JOURNAL OF RESPIRATION
2010年
21期
1285-1286
,共2页
张君利%王春%徐杰%陶毅强%李伟林
張君利%王春%徐傑%陶毅彊%李偉林
장군리%왕춘%서걸%도의강%리위림
沙美特罗替卡松%慢性阻塞性肺疾病%稳定期%急性加重期%血气
沙美特囉替卡鬆%慢性阻塞性肺疾病%穩定期%急性加重期%血氣
사미특라체잡송%만성조새성폐질병%은정기%급성가중기%혈기
Salmeterol/Fluticasone%Chronic obstructive pulmonary disease%Stable phase%Acute exacerbation phase%Blood gases
目的 探讨慢性阻塞性肺疾病(COPD)稳定期应用沙美特罗替卡松粉吸入治疗对急性加重期血气的影响.方法 34例从未正规使用吸入糖皮质激素+吸入长效β2受体激动剂联合治疗的中、重度COPD患者,前一次慢性阻塞性肺疾病急性加重期(AECOPD)发病病情稳定后应用沙美特罗替卡松粉吸入剂(舒利迭)治疗直至因发生AECOPD再次入院.观察两次的pH、动脉血氧分压(PaO2)、动脉血二氧化碳分压(PaCO2)值的比较.结果 后一次PaO2显著高于前一次住院PaO2(P<0.05);后一次PaCO2显著低于前一次PaCO2值(P<0.05),前后两次pH比较差异无统计学意义.结论 中、重度COPD稳定期吸入沙美特罗50μg/丙酸氟替卡松500μg复方制剂可以明显改善AECOPD患者的病情严重程度和血气指标.
目的 探討慢性阻塞性肺疾病(COPD)穩定期應用沙美特囉替卡鬆粉吸入治療對急性加重期血氣的影響.方法 34例從未正規使用吸入糖皮質激素+吸入長效β2受體激動劑聯閤治療的中、重度COPD患者,前一次慢性阻塞性肺疾病急性加重期(AECOPD)髮病病情穩定後應用沙美特囉替卡鬆粉吸入劑(舒利迭)治療直至因髮生AECOPD再次入院.觀察兩次的pH、動脈血氧分壓(PaO2)、動脈血二氧化碳分壓(PaCO2)值的比較.結果 後一次PaO2顯著高于前一次住院PaO2(P<0.05);後一次PaCO2顯著低于前一次PaCO2值(P<0.05),前後兩次pH比較差異無統計學意義.結論 中、重度COPD穩定期吸入沙美特囉50μg/丙痠氟替卡鬆500μg複方製劑可以明顯改善AECOPD患者的病情嚴重程度和血氣指標.
목적 탐토만성조새성폐질병(COPD)은정기응용사미특라체잡송분흡입치료대급성가중기혈기적영향.방법 34례종미정규사용흡입당피질격소+흡입장효β2수체격동제연합치료적중、중도COPD환자,전일차만성조새성폐질병급성가중기(AECOPD)발병병정은정후응용사미특라체잡송분흡입제(서리질)치료직지인발생AECOPD재차입원.관찰량차적pH、동맥혈양분압(PaO2)、동맥혈이양화탄분압(PaCO2)치적비교.결과 후일차PaO2현저고우전일차주원PaO2(P<0.05);후일차PaCO2현저저우전일차PaCO2치(P<0.05),전후량차pH비교차이무통계학의의.결론 중、중도COPD은정기흡입사미특라50μg/병산불체잡송500μg복방제제가이명현개선AECOPD환자적병정엄중정도화혈기지표.
Objective Discuss the effect of the Salmeterol/Fluticasone powder inhalational treatment on acute exacerbation phase blood gases at the stable phase of chronic obstructive pulmonary disease(COPD). Methods Thirty-four cases of middle and advanced COPD patients who had never received the combination therapy of the inhalational glucocorticoid and long-acting β2 receptor stimulant were treated with the Salmeterol/Fluticasone powder inhalation (retiedde) until admitted to hospital again due to the occurrence of acute exacerbation chronic obstructive pulmonary disease (AECOPD). Observe the comparison of the pH, arterial partial pressure of oxygen (PaO2) and arterial partial pressure of carbon dioxide (PaCO2) values of the two hospitalizations. Results The latter hospitalization PaO2 was significantly higher than the previous PaO2 ( P <0.05). The latter PaCO2 was significantly higher than the previous PaCO2 (P <0.05). And the two hospitalization pH values had no significant difference.Conclusions The inhalation of Salmeterol 50μg/Fluticasone 500 μg compound preparation at the middle and advanced COPD stable phase will significantly improve the patients' condition and blood gases during the AECOPD.